Taking an engineering approach to building biological systems – engineering biology – has spectacular potential to revolutionise how we diagnose and treat disease.
Emerging biotech company Stimuliver, co-founded
by the University of Edinburgh’s Professor David Hay, has announced financing
of £1.7m for its regenerative stem cell therapy to treat acute and chronic
liver diseases.
Student startups from the University of Edinburgh have secured over £30m in combined investment over the last year, nearly triple the amount compared to the previous year.
A business commercialisation
programme, which helps innovative companies using Artificial Intelligence (AI)
to maximise their full potential, has announced its new 2022/23 cohort.
Eight of 28 finalists in Scotland’s largest company creation programme for the university sector are from the University of Edinburgh, the organisers of Converge 2022 have announced.
